Tevogen Bio’s Mittul Mehta to Speak at Startup Forum

Boston

Mittul Mehta, Chief Information Officer of Tevogen Bio Inc. and Head of Tevogen.AI, will appear as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025, at the Sheraton Boston Hotel. The panel will address how scaling companies use Databricks technologies, and Mehta will present Tevogen.AI’s application of advanced data and AI tools, including the PredicTcell™ platform developed in collaboration with Microsoft and Databricks.

Key panel and focus

The Startup Forum will bring together early-stage innovators and venture capital leaders to discuss scaling technology and data infrastructures. Mehta will join industry peers Chris Gervais, Chief Technology Officer of Codametrix, and Stavros Papadopoulos, Chief Executive Officer of TileDB. The session will be moderated by Tony Pezzullo, Principal at SignalFire. Topics on the agenda include building production-ready AI systems, data governance during rapid growth, and practical approaches to accelerating time-to-value for life sciences applications.

What Mehta will discuss

Mehta’s participation will emphasize Tevogen.AI’s integration of advanced analytics and machine learning into precision immunotherapy development. The PredicTcell™ platform is presented as a data-driven system designed to accelerate discovery and development workflows for cellular therapies. Development of PredicTcell™ involved a technical collaboration with both Microsoft and Databricks, aiming to combine scalable compute, data engineering, and AI model deployment to reduce experimental timelines and improve candidate selection.

Event logistics

The Databricks DATA + AI World Tour stop in Boston will be held at the Sheraton Boston Hotel on October 8, 2025. The Startup Forum forms part of a broader program of sessions and demonstrations focused on AI, data platforms, and enterprise applications. The program will feature panels, technical sessions, and practical case studies intended for technology leaders, startup founders, and investors.

Company background and recent developments

Tevogen Bio Inc., based in Warren, N.J., is developing cell-based immunotherapies and supporting technologies to accelerate drug discovery through AI. In June 2025, the company announced an expansion of its corporate headquarters, more than doubling its footprint in a newly leased space that previously housed CAPTRUST, a national investment advisory firm. The move is intended to support initiatives such as Tevogen.AI and a Generics & Biosimilars division, with the stated aims of improving operational efficiency and fostering cross-team collaboration.

The company has reported an estimated risk-adjusted net present value (rNPV) of over $325 million for its lead program, TVGN 116, in the United States. Tevogen.AI is described as a strategic priority intended to accelerate drug discovery by applying AI-driven analysis to immunotherapy research, candidate selection, and development planning.

Contact and additional information

For media or other inquiries related to Tevogen Bio, the company can be contacted at communications@tevogen.com. Attendees and observers of the Databricks event can expect sessions that combine technical depth with startup-focused perspectives on scaling data and AI infrastructure.

Context and relevance

The participation of technology and life sciences leaders in events such as the Databricks DATA + AI World Tour highlights growing cross-industry interest in applying scalable data platforms and AI to drug discovery and biopharmaceutical development. Startups and established firms increasingly seek to pair domain expertise with enterprise-grade data engineering and machine learning tooling to accelerate research timelines, manage regulatory and operational complexity, and enable reproducible, data-driven decision making.

What to expect from the Startup Forum

• Practical examples of scaling data infrastructure for early-stage companies.
• Discussion of partnerships between startups and platform providers to speed deployment of AI in regulated industries.
• Insight into investor priorities when assessing AI-enabled life sciences companies.
• Cross-company perspectives on technical and organizational challenges when moving from research prototypes to production systems.